Experienced in BRCA Positive Breast Cancer

Dr. Jasgit C. Sachdev

Hematology Oncology | Hematology | Oncology
1931 E Brentrup Dr, 
Tempe, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in BRCA Positive Breast Cancer
1931 E Brentrup Dr, 
Tempe, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jasgit Sachdev is a Hematologist Oncology specialist and a Hematologist in Tempe, Arizona. Dr. Sachdev is rated as an Experienced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Testicular Yolk Sac Tumor, and Breast Cancer. Dr. Sachdev is currently accepting new patients.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1931 E Brentrup Dr, Tempe, AZ 85283

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Enrollment Status: Recruiting
Publish Date: February 08, 2024
Intervention Type: Biological, Combination product
Study Drug: CRX100
Study Phase: Phase 1
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: November 25, 2025
Intervention Type: Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Drug
Study Drug: AGEN-2034 PD-1 Antibody
Study Phase: Phase 1/Phase 2
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Enrollment Status: Terminated
Publish Date: April 17, 2025
Intervention Type: Drug
Study Drug: BDTX-189
Study Phase: Phase 1
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Enrollment Status: Terminated
Publish Date: December 06, 2022
Intervention Type: Biological
Study Drug: RPTR-168
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: July 28, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

35 Total Publications

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Journal: Investigational new drugs
Published: February 13, 2023
Similar Doctors
Advanced in BRCA Positive Breast Cancer
Dr. Erkut H. Borazanci
Oncology
Advanced in BRCA Positive Breast Cancer
Dr. Erkut H. Borazanci
Oncology

Honorhealth Ambulatory

10510 N 92nd St, Fl 2, 
Scottsdale, AZ 
 (16.0 miles away)
480-320-1350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erkut Borazanci is an Oncologist in Scottsdale, Arizona. Dr. Borazanci is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Familial Pancreatic Cancer. Dr. Borazanci is currently accepting new patients.

Experienced in BRCA Positive Breast Cancer
Dr. Jasleen K. Khanuja
Hematology Oncology | Hematology | Oncology
Experienced in BRCA Positive Breast Cancer
Dr. Jasleen K. Khanuja
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

695 S Dobson Rd, 
Chandler, AZ 
 (4.3 miles away)
480-821-2838
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jasleen Khanuja is a Hematologist Oncology specialist and a Hematologist in Chandler, Arizona. Dr. Khanuja is rated as an Advanced provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Severe Congenital Neutropenia, and Breast Cancer. Dr. Khanuja is currently accepting new patients.

Experienced in BRCA Positive Breast Cancer
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
Experienced in BRCA Positive Breast Cancer
Dr. Sharon M. Ondreyco
Hematology Oncology | Hematology | Oncology
7200 W Bell Rd Bldg A, 
Glendale, AZ 
 (26.8 miles away)
623-487-4822
Languages Spoken:
English
See accepted insurances

Sharon Ondreyco is a Hematologist Oncology specialist and a Hematologist in Glendale, Arizona. Dr. Ondreyco is rated as a Distinguished provider by MediFind in the treatment of BRCA Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Chronic Lymphocytic Leukemia (CLL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sachdev's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile